Last updated: July 31, 2026
Pentamidine isethionate is a mature, low-volume anti-infective used mainly for Pneumocystis jirovecii pneumonia (PCP) treatment and prophylaxis, with additional use against leishmaniasis and African trypanosomiasis. Its core composition-of-matter and regulatory exclusivities expired decades ago. The commercial market is generic, price-sensitive and procurement-driven, with limited opportunity for branded revenue growth.
Financial performance is shaped by hospital demand, public-health use, manufacturing continuity and supply availability rather than prescription-market expansion. No major pharmaceutical company separately reports global pentamidine isethionate revenue.
What is pentamidine isethionate used for?
Pentamidine isethionate is the salt form used in injectable and inhaled pentamidine products. The drug belongs to the aromatic diamidine class of anti-infectives.
| Clinical use |
Typical role |
| Pneumocystis jirovecii pneumonia |
Treatment, particularly when standard therapy is unsuitable or ineffective |
| PCP prophylaxis |
Alternative prophylaxis, including inhaled administration in selected patients |
| Visceral leishmaniasis |
Use varies by geography and treatment protocol |
| African trypanosomiasis |
Use is concentrated in endemic settings and public-health programs |
The principal commercial demand in the United States comes from hospitals and specialty pharmacies treating immunocompromised patients. Demand is linked to HIV care, hematologic malignancies, organ transplantation, corticosteroid exposure and other forms of immunosuppression.
The FDA label identifies pentamidine isethionate injection for the treatment of Pneumocystis jirovecii pneumonia and identifies inhaled administration as a prophylactic option in specific settings. Administration requires medical supervision because the drug can cause hypotension, hypoglycemia, pancreatitis, nephrotoxicity, cardiac effects and other serious adverse reactions (FDA, 2023a).
How large is the pentamidine isethionate market?
The market is small relative to mainstream anti-infective categories. Public company filings generally do not report pentamidine revenue as a separate product line, and syndicated prescription datasets are less informative because a substantial share of use occurs in hospitals.
The market has four structural characteristics:
- Demand is medically necessary but episodic.
- Unit volume is low compared with common antibiotics.
- Generic competition limits pricing power.
- Supply continuity has greater commercial importance than market expansion.
Pentamidine isethionate is not a mass-market outpatient product. Injectable products are purchased through hospital pharmacy systems, group purchasing organizations, wholesalers and government channels. Inhaled use depends on specialist practice, availability of nebulization equipment and the clinical preference for alternative prophylaxis regimens.
What drives demand for pentamidine isethionate?
Demand is driven by:
- The incidence of PCP among immunocompromised patients.
- Use of alternative PCP prophylaxis when trimethoprim-sulfamethoxazole is unsuitable.
- HIV and transplant-related treatment protocols.
- Oncology and hematology patient volumes.
- Public-health programs in countries where pentamidine remains part of treatment for neglected tropical diseases.
- Hospital inventory policies and shortages of competing anti-infective products.
The market does not have a strong growth catalyst. Any volume increase is more likely to result from shifts in the immunocompromised patient population or changes in treatment guidelines than from new indications.
What is the financial trajectory for pentamidine isethionate?
Pentamidine isethionate has a mature-to-declining financial profile in branded pharmaceutical terms. Aggregate demand is relatively stable but fragmented, while supplier revenue depends on contract wins, manufacturing continuity and temporary market shortages.
| Financial factor |
Market effect |
| Generic competition |
Suppresses long-term price growth |
| Low annual volume |
Limits manufacturing scale economies |
| Hospital procurement |
Increases bid and contract pressure |
| Limited therapeutic substitution in severe PCP |
Supports baseline demand |
| Alternative prophylaxis drugs |
Caps inhaled-product growth |
| Few suppliers in some markets |
Can create short-term price volatility |
| Absence of active exclusivity |
Prevents durable premium pricing |
A supplier can generate attractive gross margins for a period if it maintains reliable supply in a constrained market. That opportunity is operational rather than patent-based. Revenue can fall quickly after new entrants restore supply or hospital contracts move to another manufacturer.
There is no credible basis for assigning a precise global revenue figure from publicly available FDA and company disclosures. Pentamidine revenue is generally embedded within broader generic injectable, hospital-product or anti-infective portfolios.
Does pentamidine isethionate have significant commercial growth potential?
The commercial growth potential is limited. The strongest opportunities are tactical:
- Securing hospital and government supply contracts.
- Maintaining uninterrupted production of sterile injectable vials.
- Entering markets with few approved suppliers.
- Providing ready-to-use or operationally simpler presentations.
- Expanding access in endemic regions through public-health procurement.
- Managing supply reliability better than competing generic manufacturers.
A new branded product would face a difficult return-on-investment case unless it offered a material advantage in administration, safety, stability, delivery equipment or public-health access.
What is the FDA regulatory status of pentamidine isethionate?
Pentamidine isethionate is an FDA-approved legacy anti-infective available through generic drug products. The main U.S. dosage forms are injectable products and inhalation products or solutions associated with nebulized administration.
The FDA-approved product profile is centered on:
- Pentamidine isethionate injection, commonly supplied in a 300 mg vial.
- Inhaled pentamidine products for PCP prophylaxis, historically including NebuPent-associated products.
- Hospital-administered products requiring preparation, monitoring and specialized handling.
FDA labeling warns that pentamidine can produce clinically significant metabolic, renal, cardiovascular and pancreatic adverse effects. These safety characteristics support continued use in selected patients but restrict broad substitution into routine outpatient anti-infective treatment (FDA, 2023a; FDA, 2023b).
What is the Orange Book status of pentamidine isethionate?
The Orange Book lists approved pentamidine isethionate products and identifies reference-listed-drug relationships where applicable. The commercial significance of Orange Book listings is limited because the principal patents and exclusivity periods associated with the original products have expired.
The current market is therefore governed mainly by:
- ANDA approvals.
- Product-specific labeling.
- Manufacturing capacity.
- Drug-quality compliance.
- Wholesale and hospital contracts.
- FDA supply and shortage conditions.
A current Orange Book review should be performed at the product level because listing status, marketing status and reference-product relationships can change when manufacturers discontinue or relaunch products (FDA, 2024).
What patents protect pentamidine isethionate?
No commercially material, enforceable composition-of-matter patent protection remains for pentamidine isethionate in the United States. The active ingredient was developed in the mid-20th century, placing its foundational intellectual property well outside the modern patent term.
The relevant patent categories are historical or peripheral:
| Patent category |
Current commercial relevance |
| Pentamidine composition patents |
Expired |
| Salt and chemical-form patents |
Expired or commercially immaterial |
| Injectable formulations |
Generally expired |
| Inhalation formulations |
Historical protection largely expired |
| Nebulizer or delivery technology |
May be relevant to a device owner, but not to the active ingredient itself |
| Manufacturing processes |
Possible trade-secret value; limited blocking-patent value |
| Method-of-use patents |
No known durable U.S. exclusivity supporting the current generic market |
The main remaining barriers are regulatory and manufacturing barriers, not patent barriers. Sterile injectable production, validated filling processes, quality control and reliable raw-material sourcing can be more difficult than obtaining freedom to operate.
When did pentamidine isethionate lose exclusivity?
Pentamidine isethionate lost practical market exclusivity decades ago. Its current market does not depend on an active new-drug, orphan-drug or pediatric exclusivity period.
| Exclusivity type |
Current status |
| New chemical entity exclusivity |
Expired |
| Original product patent term |
Expired |
| Orphan-drug exclusivity |
No current exclusivity controlling the general pentamidine market |
| Pediatric exclusivity |
No current commercial significance |
| Regulatory exclusivity for legacy products |
Expired |
| Generic approval pathway |
Available, subject to product-specific FDA requirements |
Because the drug predates the Hatch-Waxman era, historical patent and exclusivity analysis is less important than the approval status of individual manufacturers and presentations.
Which companies manufacture or supply pentamidine isethionate?
The supplier base has included branded legacy manufacturers and multiple generic injectable companies. Product availability varies by country and over time. U.S. hospital procurement may involve generic manufacturers, contract manufacturers, wholesalers and repackagers.
Manufacturers can change their marketing status without altering the underlying competitive structure. A product may remain FDA-approved while being listed as discontinued or unavailable from a particular supplier.
The practical competitive questions are:
- Which manufacturers have active commercial inventory?
- Which suppliers maintain FDA-compliant sterile injectable capacity?
- Which companies have current hospital contracts?
- Which suppliers have reliable pentamidine active pharmaceutical ingredient sources?
- Are competing products available in the same vial strength and presentation?
FDA approval alone does not guarantee continuous commercial supply.
Are there Paragraph IV challenges for pentamidine isethionate?
Paragraph IV litigation is unlikely to be a central feature of the current pentamidine isethionate market. The principal patents associated with the original drug and its established dosage forms expired long ago. Generic entrants therefore generally do not need to challenge a commercially important patent estate to enter the market.
Where an ANDA applicant encounters a listed patent, the legal risk depends on:
- Whether the patent remains unexpired.
- Whether it is listed against the relevant reference product.
- Whether the applicant files a Paragraph IV certification.
- Whether the patent covers the proposed formulation or method.
- Whether the brand owner brings an action within the statutory period.
For this legacy product, abbreviated new drug approval, product quality and supply economics are more important than Hatch-Waxman litigation.
What patent litigation and settlement agreements affect pentamidine isethionate?
No major current U.S. patent litigation or settlement agreement is broadly associated with the active ingredient. Historical disputes, if any, would have limited relevance to present commercial economics because the foundational exclusivity period has ended.
The absence of meaningful litigation reduces legal entry risk. It does not eliminate commercial risk. Suppliers can still face FDA warning letters, manufacturing observations, recalls, product-quality disputes, contract claims and liability exposure related to administration or adverse events.
Is there biosimilar risk for pentamidine isethionate?
Pentamidine isethionate is a small-molecule drug, not a biologic. Biosimilar regulation under the Biologics Price Competition and Innovation Act does not apply.
Competitive entry occurs through conventional generic-drug pathways, principally ANDAs under the Federal Food, Drug, and Cosmetic Act. The relevant competition is among generic manufacturers and dosage-form suppliers, not biosimilar developers (FDA, 2024).
What generic entry risks exist for pentamidine isethionate?
Generic entry risk is already realized rather than prospective. The market has long been open to generic competition.
The principal risks to an incumbent supplier are:
- New low-cost entrants.
- Hospital formulary substitution.
- Group purchasing organization rebidding.
- Wholesale price compression.
- Loss of a government contract.
- Manufacturing interruption by a competitor that creates temporary demand shifts.
- A replacement product with easier preparation or administration.
The principal risks to a new entrant are different:
- Small addressable volume.
- High sterile-manufacturing costs.
- Limited ability to differentiate an old molecule.
- Regulatory expenses disproportionate to annual sales.
- Dependence on a small number of hospital and public-health buyers.
- Potentially volatile demand.
How strong is the pentamidine isethionate patent estate?
The patent estate is weak for blocking purposes and has little residual value as a licensing asset.
| Estate component |
Assessment |
| Core molecule |
No meaningful remaining exclusivity |
| Salt form |
No meaningful blocking position expected |
| Injection |
Mature generic technology |
| Inhalation |
Limited differentiation and largely expired historical protection |
| Manufacturing |
Process know-how may have operational value |
| Device delivery |
Potentially relevant only where a proprietary device is used |
| Method of use |
Limited current exclusivity value |
A company evaluating pentamidine should focus on regulatory diligence, manufacturing quality, supply-chain resilience and commercial contracting rather than patent acquisition.
How does pentamidine compare with alternative PCP therapies?
Pentamidine is usually an alternative rather than the first-line choice for PCP treatment or prophylaxis. Trimethoprim-sulfamethoxazole is widely used when tolerated. Atovaquone, dapsone-based regimens and clindamycin-primaquine combinations can also compete depending on the clinical setting.
| Therapy |
Competitive position |
| Trimethoprim-sulfamethoxazole |
Common first-line option; broad availability |
| Atovaquone |
Oral alternative, often used when tolerability is a concern |
| Dapsone-based regimens |
Alternative prophylaxis for selected patients |
| Pentamidine |
Important alternative when oral options are unsuitable or ineffective |
| Clindamycin-primaquine |
Alternative treatment regimen in selected cases |
Pentamidine retains clinical value because severe PCP and treatment intolerance can leave physicians with limited options. Its adverse-effect profile prevents it from becoming a broad replacement for more convenient oral therapies.
What manufacturing and geographic barriers affect the market?
The highest barriers are associated with sterile manufacturing and distribution.
United States
U.S. demand is concentrated in hospitals, specialty centers and public-health systems. FDA-compliant sterile production, pharmacovigilance and reliable wholesaler access determine commercial viability.
Europe
European demand is fragmented across national procurement systems. Pricing is influenced by centralized or regional tenders, reimbursement policies and country-specific hospital purchasing.
Endemic regions
Pentamidine remains relevant in parts of Africa and other regions affected by leishmaniasis and trypanosomiasis. Public-health procurement can generate substantial clinical importance without producing high commercial margins. Donor-funded programs and government tenders often determine access and pricing.
Manufacturing
Manufacturing risks include:
- Limited qualified API sources.
- Sterile filling capacity.
- Container-closure and stability requirements.
- Batch-release testing.
- Small production runs.
- Low inventory incentives.
- Dependence on specialized hospital distribution.
These conditions can create short-term price increases even when long-term demand is flat.
What are the likely generic launch scenarios?
A new generic entrant would most likely pursue one of three strategies:
- Hospital injectable entry: Compete on reliable supply, contract pricing and vial availability.
- Specialty inhalation entry: Target a narrower prophylaxis market with a differentiated delivery format.
- Public-health supply entry: Compete for government or donor-funded tenders in endemic countries.
The injectable market is more commercially defensible because hospitals require dependable supply and may tolerate limited supplier concentration. The inhaled market has a narrower opportunity and greater dependence on clinical practice, equipment and alternative prophylaxis.
Key Takeaways
- Pentamidine isethionate is a mature generic anti-infective with low-volume, hospital-centered demand.
- No meaningful core patent or regulatory exclusivity remains.
- Paragraph IV litigation and biosimilar competition are not major market factors.
- Financial performance depends on supply reliability, hospital contracts and public-health procurement.
- The strongest commercial barrier is sterile manufacturing, not intellectual property.
- Revenue is not separately disclosed by major pharmaceutical companies, preventing a reliable standalone market-size estimate from public filings.
- Pentamidine remains clinically important as an alternative PCP therapy despite competition from oral regimens.
- Generic entry is legally accessible but commercially difficult because the market is small and price-sensitive.
FAQs About Pentamidine Isethionate Market and Exclusivity
Is pentamidine isethionate still profitable for generic manufacturers?
It can be profitable when supplier competition is limited or a manufacturer secures hospital and government contracts. The opportunity is usually operational and contract-based rather than driven by premium pricing.
Does pentamidine isethionate have an active U.S. patent?
No commercially important core patent protection is expected to remain for the active ingredient or its established dosage forms. Product-level Orange Book review is still required for any specific ANDA or reference product.
Can a company launch a generic pentamidine injection without Paragraph IV litigation?
Yes, where no unexpired listed patent blocks the proposed product. The applicant must still satisfy FDA requirements for pharmaceutical equivalence, bioequivalence where applicable, manufacturing quality and labeling.
Is inhaled pentamidine a growth market?
Growth is limited. Inhaled pentamidine remains relevant for selected PCP prophylaxis patients, but oral alternatives and changes in clinical practice constrain broad expansion.
What is the main investment risk in pentamidine isethionate?
The main risk is weak market scale combined with manufacturing and procurement concentration. A supplier may face low baseline volume, price compression and rapid revenue loss if a hospital contract ends or competitors restore supply.
References
-
U.S. Food and Drug Administration. (2023a). Pentamidine isethionate injection prescribing information. FDA.
-
U.S. Food and Drug Administration. (2023b). Drugs@FDA: FDA-approved drug products database. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. National Library of Medicine. (2024). DailyMed: Pentamidine isethionate drug labels. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA. https://purplebooksearch.fda.gov/
